Huawei at MWC 2023: Intelligent World Needs Stronger ICT Industry and Digital Economy
28.2.2023 19:41:00 EET | Business Wire | Press release
During MWC Barcelona 2023, Huawei will be meeting with operators, industry partners, and other key opinion leaders from around the world to discuss "GUIDE to the Intelligent World". Together, they will look at how to use the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity in an intelligent world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006057/en/
Huawei's Hall 1 exhibition booth at MWC Barcelona 2023 (Photo: Huawei)
Huawei’s main exhibition booth in MWC Barcelona's Hall 1 is designed around the concept of “Intelligent Future, Full of Hope”. At the booth, Huawei painted a picture of an era fueled by the digital economy and defined by collaboration that is more vibrant and full of unlimited possibilities. At the event, Huawei is also showcasing its latest products and solutions that deliver ultimate 5G experiences, premium and intelligent ultra-broadband connectivity, digital and intelligent transformation, and their Green 1-2-3 solution. Huawei's offerings show a clear commitment to innovating for the 5.5G era, creating value for customers, and stimulating the digital economy.
By the end of 2022, 5G had already proven to be a global commercial success, with over a billion mobile users connecting with 5G. Leading operators in China, South Korea, Switzerland, Finland, and Kuwait have already achieved 5G user penetration rates of more than 30%, and more than 30% of their traffic comes from 5G.
According to Ookla's latest 5G City Benchmark Report, Huawei has played an important part in 5G network construction in all of the top 10 cities among the world's 40 representative 5G-enabled cities. It's important to note that 5G performance results in these 10 cities show that the 5G networks constructed by Huawei offer the best experience.
Following on from Huawei's concept of "Striding Towards the 5.5G Era" that was proposed in July 2022, Huawei is highlighting the five major characteristics of the 5.5G era: 10 Gbps experiences, full-scenario interconnection, integrated sensing and communication, L4 autonomous driving networks, and green ICT. Leading global operators, standards organizations, and industry ecosystem partners are coming together to promote innovation and exploration for this 5.5G era, as it will create more new applications and business opportunities.
Ongoing and robust investment into ICT infrastructure directly spurs growth within the digital economy. A third-party report shows that, as new networks evolve from one generation to another, this effect will be further amplified by 15%. Looking towards the future, we believe the GUIDE business blueprint that combines both 5G and 5.5G clearly lays out how ICT evolution will progress and bring about greater value.
Together with our customers and partners, we will continue to innovate, building intelligent connectivity and redefining computing. This collaboration on innovation will create even greater value for the ICT industry and make the industry as a whole more resilient and prosperous.
Huawei’s Enterprise division is also hosting their own event at MWC 2023, themed “Leading Digital Infrastructure for New Value Together”, where they will launch more than 50 innovative products and solutions for global customers. Highlights here include their Intelligent Simplified Campus Network Solution, a series of innovative data center solutions, and business strategies for small- and medium-sized enterprises (SMEs).
In the device field, Huawei is showcasing their new HUAWEI Mate 50 series, HUAWEI WATCH Buds, HUAWEI WATCH GT Cyber, that come packed with new innovation in areas like mobile imaging, fitness and health, and smart office.
MWC Barcelona 2023 runs from February 27 to March 2 in Barcelona, Spain. Huawei showcases its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we dive into topics such as 5G business success, 5.5G opportunities, green development, digital transformation, and our vision of using the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity. For more information, please visit: https://carrier.huawei.com/en/events/mwc2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006057/en/
Contact information
Olivia Zhang
+86-15013066795 / +44-7444720703
zhangningning7@huawei.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom